Bank of America analyst Michael Ryskin has revised his outlook on Icon (ICLR, Financial), reducing the stock's price target from $255 to $204 while maintaining a Buy rating. The adjustment comes as investor sentiment dims for sectors like Life Sciences, Diagnostic Tools, and Contract Research Organizations.
Ryskin highlights several challenges affecting these industries. They face policy shifts introduced during the Trump Administration, which include potential National Institutes of Health (NIH) budget cuts and the impact of global tariffs. Additionally, broader economic concerns, notably those related to China, add to the cautious outlook.
As these companies prepare for upcoming earnings reports, these factors weigh heavily on their market prospects, influencing financial forecasts and investor expectations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Icon PLC (ICLR, Financial) is $222.38 with a high estimate of $275.00 and a low estimate of $160.00. The average target implies an upside of 53.88% from the current price of $144.51. More detailed estimate data can be found on the Icon PLC (ICLR) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Icon PLC's (ICLR, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Icon PLC (ICLR, Financial) in one year is $268.47, suggesting a upside of 85.78% from the current price of $144.51. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Icon PLC (ICLR) Summary page.
